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Maesopsin 4-O-b-glucosideABSTRACT
Objective: To investigate the antitumor effect of maesopsin 4-O-b-glucoside (TAT2)
isolated from the leaves of Artocarpus tonkinensis (A. tonkinensis) A. Chev. ex Gagnep.
Methods: The antitumor activity of TAT2 was evaluated in Lewis lung carcinoma
(LLC) tumor-bearing mice. BALB/c mice had tumors induced by implantation with
2 × 106 LLC cells into the subcutaneous right posterior ﬂank. Tumor-bearing mice were
treated orally with a range of doses of TAT2 and a standard drug, doxorubicin. Animals
were observed for tumor growth and mortality rate. Blood was collected to determine
hematological and biochemical parameters.
Results: TAT2 was isolated from an ethanolic extract of A. tonkinensis leaves. Its
structure was determined by MS and NMR spectroscopy, and identiﬁed as TAT2. The
compound did not show acute toxicity at the highest dose tested (2000 mg/kg body
weight). TAT2 exhibited antitumor activity by decreasing tumor growth, increasing the
survival rate, and ameliorating some hematological and biochemical parameters at doses
of 100 and 200 mg/kg body weight (P < 0.05).
Conclusions: These results indicate that TAT2 possesses clear antitumor activity. Due to
its bioavailability and low toxicity, and the fact that it could be isolated in a large scale
from A. tonkinensis leaves, the compound shows promise as a potential anticancer drug.1. Introduction
Artocarpus tonkinensis (A. tonkinensis) A. Chev. ex Gagnep.
is usually found in North Vietnam. The decoction of its leaves
and roots is used in folk medicine to treat backache, rheumatism
and joint disorders [1]. A crude extract from A. tonkinensis leaves
has been used successfully in Vietnam as an immunosuppressive
agent for skin transplantation in mice [2]. In recent years, our
group has focused on the chemical identiﬁcation of the active
ingredients in A. tonkinensis leaves. We demonstrated thatﬂavonoid glycosides such as maesopsin 4-O-b-glucoside
(hovetrichoside C, TAT2), alphitonin-O-b-glucoside, artonkin-
40-O-b-glucopyranosid, and astragalin strongly contributed to
its immunosuppressive and anti-inﬂammatory activities [3,4].
These compounds have potent anti-proliferative and anti-
inﬂammatory effects both in vitro and in vivo [4,5]. The anti-
inﬂammatory effects demonstrated in a rat model of arthritis
correlated well with the inhibition of mitogen-induced T-cell
proliferation [6]. Furthermore, the main compound, TAT2,
inhibited the growth of OCI-AML cells (and additional acute
myeloid leukemia cells) but not Jurkat cells, a T lymphoma.
Moreover, gene expression proﬁling identiﬁed 19 genes modu-
lated by TAT2 and, among them, indicated HMOX1 and
SRXN1 as consistently and highly upregulated [5]. Although
TAT2 is a major component (yield 0.2%) of A. tonkinensis
leaves, its antitumor activity has not yet been studied in vivo.
Due to its promising pharmacological properties, this study
focused on the large-scale isolation of TAT2 and its potential
anticancer effect in vivo for possible use in alternative medicine.rticle under the CC BY-NC-ND license (http://
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2.1. Chemicals
Fractionation was performed over DIAION HP20 resin
(Supelco, Bellefonte, PA, USA), Sephadex® LH20 (Sigma, St.
Louis, MO, USA); silica gel (Merck). Dulbecco's modiﬁed Ea-
gle's medium and MEM nonessential amino acid were obtained
from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum and
antibiotics were purchased from Sigma Chemical Co. (St. Louis,
MO., USA).
2.2. Plant material, extraction and isolation
Leaves of A. tonkinensis were collected in Hanoi, Vietnam
(December 2013) and identiﬁed by the taxonomist -Ngo Van
Trai (Institute of Materia Medica, Hanoi, Vietnam). The voucher
specimen (Nr. 1482-AT-2013) was deposited in the Institute of
Chemistry, Vietnam Academy of Science and Technology.
Dried ground leaves of A. tonkinensis (12 kg) were extracted
with 70% EtOH (each 36 L, overnight, ×3 times) at room tem-
perature. The extract was ﬁltered and concentrated in vacuo
(temperature 45–60 C) to remove EtOH affording an aqueous
solution, and partitioned with n-hexan. The aqueous phase was
dissolved in water and loading over Diaion HP20 column, washed
with water, 50% aq. MeOH and MeOH to give 4 fractions
(Fr1/ Fr4). Fr3 (eluting with 50% MeOH, 740 g) was chroma-
tographed over Sephadex LH20 eluted with MeOH to give 4 sub-
fractions (Fr3.1/ Fr3.4). Fraction 3 (Fr3.3, 350 g) was further
chromatographed over silica gel, eluted with EtOAc-MeOH-H2O
(75:25:1/ 70:30:2 and then 65:35:5) to afford 5 sub-fractions
(Fr3.3.1/ Fr3.3.5). Sub-fraction 4 (Fr3.3.4, 40 g) was further
puriﬁed by CC (silica gel, EtOAc-MeOH-H2O, 4:1:0.1) to afford
compoundTAT2 (24 g, yield 0.2%, comparedwith driedmaterial).
2.3. Identiﬁcation of purity and characterization of
compound TAT2
The purity of compound TAT2 was determined by HPLC-
DAD (HPCHEM) using a Synergi Fusion RP80A column
(250 mm × 2.0 mm i.d.) at 25 C. UV spectrum was recorded
from 190 nm to 400 nm. The mobile phase consisted of A, water
containing 0.1% formic acid, and B, acetonitrile containing
0.1% formic acid. The elution gradient was performed using a
pump from 10% to 35% B for 50 min; 35%–80% B from 50 to
55 min at a ﬂow rate of 0.25 mL/min. Detection was carried over
60 min at a ﬂow rate of 0.25 mL/min. Detection was carried out
at 290 and 294 nm. The injection volume was 5 mL. The HPLC
chromatogram of TAT2 showed major peak with retention time
(Rt) at 20.39 min, percentage 95.8%.
HR-ESI MS spectrum was obtained on QStar Pulsar (Applied
Biosystems).1HNMR (500.13MHz) and 13CNMR (125.77MHz)
spectral data were measured in methanol-d4 (CD3OD) on a Bruker
Avance 500 NMR spectrometer, at 25 C. Chemical shifts were
expressed in d (ppm) downﬁeld from TMS as an internal standard,
and coupling constants were reported in Hertz.
2.4. Animals
Male and female albino BALB/c mice (8–10 weeks old) were
obtained from the Institute of Biotechnology, Vietnam Academyof Science and Technology (Hanoi, Vietnam). All mice were
housed in a temperature-controlled room on a 12-h light/12-h
dark cycle with food and water provided ad libitum. Experi-
ments were performed in accordance with Vietnamese ethical
laws and European Communities Council Directives of
November 24, 1986 (86/609/EEC) guidelines for the care and
use of laboratory animals.
2.5. Acute toxicity study
The acute oral toxicity of the compound was tested using the
OECDGUIDELINE 420 [7]. Mice were administered TAT2 orally
by using a stomach tube. Animals received the compound in serial
doses of 2000 mg/kg; 1500 mg/kg; 1000 mg/kg; and 500 mg/kg
body weight (bw) after 4 h diet. They were observed for 14 d to
monitor survival and toxic symptoms.
2.6. Antitumor study
The tumor cell line Lewis lung carcinoma (LLC) was kindly
provided by Dr. Jeanette Maier, University of Milan, Italy. The
cells were maintained in 75 cm2 tissue culture ﬂasks containing
Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA),
1% non-essential amino acids and 1% antibiotics (Sigma, St.
Louis, MO, USA) at 37 C in a humidiﬁed 5% CO2 atmosphere.
Cells were subcultured every 2–3 d.
2.7. Treatment schedule
Mice were tumorized by implantation with 2 × 106 LLC cells
(in 0.2 mL serum-free DMEM) into the subcutaneous right
posterior ﬂank. Drug treatment began when the tumor volume
reached approximately 100 mm3. The day the LLC cells were
implanted was day 0 of the experiment. Tumor-bearing mice
were divided into six groups of ten: Group Ⅰ received distilled
water orally and served as a negative control; Group Ⅱ received a
standard drug (doxorubicin) at a dose of 5 mg/kg/day; animals in
Group Ⅲ, Ⅳ and Ⅴ were treated with TAT2 at doses of 50 mg/
kg, 100 mg/kg and 200 mg/kg bw, respectively. All compounds
were administered orally once daily. The animals were observed
every day for tumor growth. Body weight, tumor width and
length were assessed every 7 d.
2.8. Determination of tumor volume
Based on tumor size, which was measured by calipers, tumor
volume was calculated using the following formula [8,9]: volume
(cm3) = W2 × L/2, where W is the tumor width and L is the
tumor length. The percent of tumor growth inhibition was
determined using the following equation: % of tumor
inhibition = 100% − (100 × MT × MC−1), where MC is the
mean tumor volume of the control group and MT is the mean
tumor volume of the treated group.
2.9. Measurement of hematological parameters
Blood from the control and TAT2-treated groups were
collected to determine hematological parameters. Blood was
obtained from the tail vein and used for the detection of he-
moglobin (Hb), red blood cells (RBC), white blood cells
Figure 2. Structure of compound TAT2 isolated from the leaves of
A. tonkinensis.
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corpuscular (cell) volume, and mean corpuscular hemoglobin
concentration using a blood automatic analyzer (AU680,
Beckman Coulter). Levels of other enzymes in the sera such as
serum glutamate pyruvate transaminase (SGPT), serum aspartate
aminotransferase (SGOT) and creatinine were also measured.
2.10. Statistical analysis
Data are expressed as the mean ± SD. Statistical analyses and
signiﬁcance, as measured by one-way analysis of variance
(ANOVA), were performed using GraphPad PRISM software
version 4.0 (GraphPad Software, USA). In all comparisons,
P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Chemical analysis
In extraction experiment, 70% ethanol was used, as TAT2 is
soluble in both ethanol and water. TAT2 was isolated as aTable 1
13C and 1H NMR data of compound TAT2 [CD3OD, 125/500 MHz,
d (ppm)] (shifts of the minor compound in brackets, if different).
C dC dH (J in Hz)
2 107.59 [107.64] –
3 196.88 [196.98] –
4 158.42 [158.30] –
5 97.59 [97.26] 6.07 br s
6 171.41 –
7 93.17c [93.26]c 5.96 br s
8 174.53 [174.55] –
9 103.48 [103.67] –
10 41.94 [ 42.11] 3.10 sc [3.11 da (14)]c
10 125.58 [125.56] –
20/60 132.50 7.00 00br d"b (8.3)
30/50 115.75 [115.79] 6.59 00d"b (8.3) [6.58 00d"b (8.3)]
40 157.25c [157.22]c –
100 101.70 [101.67] 4.89 d (7.5) [4.87d (7.5)]
200 74.00 [74.06] 3.56 md
300 77.38 [77.31] 3.48 md
400 71.17 3.43 md
500 78.39c [78.32]c 3.43 md
600 62.35 3.89 br d (12), 3.70 ddd (2, 7, 12)
a Very strong AB-effect. b AA'XX0 system. c Exchangeable.
d Overlapped.
Figure 1. Analytical HPLC chromatograms of compound TAT2 (retention timyellow amorphous powder from the EtOH extract by repeated
column chromatography over DIAION HP20, sephadex LH-20
(MeOH) using appropriate solvent systems. An ion exchange
resin (Diaion HP20) column and gel-ﬁltrate (Sephadex LH20)
chromatography with appropriate solvent systems were effective
for preparing the compound on a large scale. The purity of
TAT2 was determined to be 95.8% by HPLC. HR-ESI-TOF-MS
(m/z): 473.1053 [M + Na]+(C21H22O11Na requires 473.1054).
ESI-MS (negative ions): 449 [M−H]−. 1H and 13C NMR spectral
data are shown in Table 1. The HPLC chromatogram of TAT2 is
shown in Figure 1 and its structure is shown in Figure 2.
3.2. In vivo antitumor activity of TAT2
3.2.1. Acute toxicity studies
Results from the acute toxicity study showed that TAT2
did not cause toxicity in mice even at the highest dose of
2 000 mg/kg body weight. All mice treated with TAT2 survived
and did not show any toxic symptoms or abnormal behavior at
the tested doses over the 14 d of observation (data not shown).
Therefore, TAT2 was considered safe to use to determine the
antitumor activity at lower doses (200 mg/kg, 100 mg/kg and
50 mg/kg bw).
3.2.2. Tumor growth and survival indices
In the in vivo antitumor experiment, TAT2 suppressed solid
tumor growth in a dose-dependent manner (Table 2). Although
the tumor volumes were the same for the ﬁrst 14 d between the
control group and the TAT2-treated groups, TAT2 increased at a
much slower speed than the negative control (vehicle-treated
group) over the same time period. The data collected at the end
of the study demonstrated that TAT2 showed signiﬁcant activitye 20.4 min, purity 95.8%).
Table 2
Effect of TAT2 on tumor growth in LLC tumor-bearing mice.
Groups Tumor volumes (cm3)
Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
Negative control 0.124 ± 0.037 1.264 ± 0.519 4.445 ± 1.994 6.331 ± 2.639 7.197 ± .884 10.715 ± 0.594
Doxorubicin 0.095 ± 0.009 0.469 ± 0.107 0.938 ± 0.109 1.318 ± 0.088 1.818 ± 0.072 2.586 ± 0.161
TAT2: 50 mg/kg 0.122 ± 0.009 1.214 ± 0.248 4.118 ± 1.917 6.188 ± 2.988 6.636 ± 0.798 9.477 ± 0.709
TAT2: 100 mg/kg 0.119 ± 0.017 1.181 ± 0.399 2.074 ± 0.164 4.123 ± 1.163 5.172 ± 1.359 6.915 ± 0.602
TAT2: 200 mg/kg 0.111 ± 0.008 1.193 ± 0.514 2.028 ± 0.814 3.594 ± 1.251 4.496 ± 2.289 5.224 ± 1.300
Figure 3. Percentage of tumor growth inhibition by TAT2.
Table 3
Effects of TAT2 on body weight and tumor weight in LLC-bearing mice.
Group Body weight (g) Mortality
rate
Tumor
weight (g)
Pre-treated After-treated
Negative
control
22.25 ± 2.06 28.37 ± 1.00 4/6 11.95 ± 0.72
Doxorubicin 22.00 ± 2.00 27.03 ± 1.36 0/6 2.19 ± 0.43
TAT2: 50
mg/kg
22.50 ± 1.29 27.68 ± 0.95 2/6 10.88 ± 1.10
TAT2: 100
mg/kg
22.13 ± 1.65 26.88 ± 1.11 1/6 8.38 ± 1.05
TAT2: 200
mg/kg
22.55 ± 1.86 26.33 ± 2.57 1/6 6.36 ± 1.08
Trinh Thi Thuy et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(4): 351–356354at doses of 100 mg/kg and 200 mg/kg body weight, with tumor
inhibition being 35.47% and 51.24%, respectively (Figure 3).
Tumor weights are shown in Table 3, which indicated that
growth was clearly reduced in the TAT2-treated groups atTable 4
Effect of TAT2 on hematological and biochemical parameters of tumor-bear
Parameters
Negative control Doxorubicin
WBC (109/L) 14.40 ± 0.14 9.65 ± 0.38
LYMLymphocyte (%) 82.20 ± 2.40 68.34 ± 2.45
Monocyte (%) 9.45 ± 1.48 12.12 ± 3.67
Other WBC (%) 6.25 ± 0.78 19.54 ± 12.64
RBC ( × 1012/L) 7.49 ± 0.17 10.38 ± 0.56
PLT ( × 109/L) 616.50 ± 16.26 721.15 ± 13.46
Hb (g/L) 116.00 ± 2.83 138.01 ± 3.57
MCV (fg) 42.60 ± 0.95 44.06 ± 2.12
MCH (pg) 15.16 ± 1.65 14.39 ± 1.35
MCHC (g/L) 338.00 ± 10.52 325.86 ± 1.72
SGOT (UI/L) 501.60 ± 81.19 302.16 ± 13.64
SGPT (UI/L) 51.73 ± 1.40 41.55 ± 3.63
Creatinine (UI/L) 30.26 ± 0.64 30.10 ± 1.02
MCV: Mean corpuscular volume; MCH: Mean corpuscular hemoglobin; Mdoses of 100 mg/kg and 200 mg/kg body weight compared
with the negative control (P < 0.05). The mean tumor weight
of the negative control group was (11.95 ± 0.72) g, while the
means of the TAT2 – administered groups at doses of
100 mg/kg and 200 mg/kg body weight decreased to
(8.38 ± 1.05) g and (6.36 ± 1.08) g, respectively. There was
no signiﬁcant difference between the body weights of the
tumor-bearing mice treated with TAT2 and the control group
at the end of the experiment (P > 0.05). The antitumor ac-
tivity of the compound was also measured through survival;
the survival rate improved considerably in the TAT2-treated
groups.
3.2.3. Hematological parameters
Hematological parameters are presented in Table 4. The
WBC and LYM counts were higher in the LLC tumor-bearing
mice and lower in the doxorubicin-treated group. TAT2
administration (200 mg/kg body weight) also signiﬁcantly
reduced the number of WBC and LYM compared with the
negative control group (P < 0.05). In contrast to WBC, the
number of RBC and PLT and Hb content were improved in
tumor-bearing mice treated with TAT2, but only at doses of 100
and 200 mg/kg body weight.
During the evaluation, the activities of some functional en-
zymes of the liver and kidney were also measured (Table 4).
Although there were no differences in SGOT or creatinine levels
between groups, the mean SGPT level was (43.05 ± 4.45) UI/L
in the group treated with the highest dose of TAT2 and was
signiﬁcantly decreased in comparison with the negative control
group (51.73 ± 1.40 UI/L) (P < 0.05). These results indicate that
TAT2 could ameliorate several hematological and biochemical
parameters in LLC-induced tumor-bearing mice.ing mice.
Groups
TAT2 50 mg TAT2 100 mg TAT2 200 mg
13.08 ± 0.95 12.50 ± 0.99 11.30 ± 0.42
73.54 ± 23.85 65.35 ± 2.62 70.10 ± 8.06
12.36 ± 4.21 14.50 ± 1.84 16.55 ± 5.44
14.10 ± 2.58 19.65 ± 1.48 18.35 ± 9.68
7.68 ± 0.83 9.68 ± 0.30 9.62 ± 1.53
677.84 ± 15.90 720.00 ± 38.18 714.00 ± 43.84
122.23 ± 4.38 136.50 ± 6.30 137.00 ± 25.45
42.35 ± 4.02 41.77 ± 3.06 43.95 ± 3.75
13.95 ± 2.65 13.33 ± 0.74 14.15 ± 0.35
324.60 ± 6.54 321.33 ± 9.86 323.50 ± 9.09
504.63 ± 45.98 517.05 ± 55.79 563.55 ± 62.01
48.36 ± 7.83 5760 ± 1.27 43.05 ± 4.45
30.41 ± 0.62 30.33 ± 1.15 29.95 ± 0.35
CHC: Mean corpuscular hemoglobin concentration.
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In traditional medicine, A. tonkinensis leaves are used as
immunosuppressive drugs for the treatment of arthritis. To the
best of our knowledge, our study is the ﬁrst to report phyto-
chemical investigations of the leaves of this plant. Compound
TAT2 (yield 0.2%, purity 95.8%) was isolated from a 70%
EtOH extract of A. tonkinensis leaves by repeated column
chromatography. The molecular formula of TAT2 was deter-
mined to be C21H22O11 by HR ESI MS (m/z 473.1053
[M + Na]+, C21H22O11Na requires 473.1054). The
13C NMR
spectrum revealed 21 carbons as two sets of signals due to an
isomeric hemiketal at C-2. On the basis of the MS results, NMR
spectroscopic data and comparison with previously reported data
[4,10], its structure was conﬁrmed as TAT2, the rare auronol
glycoside in nature [11].
In recent years, the cancer rate has increased, especially in
less developed countries. Identiﬁcation and development of
new chemotherapy drugs has been critical for cancer treatment.
Plants have been a rich source of natural drugs [12,13]. In
addition, compounds derived from plants are diverse in
structure and bioactivity and exhibit low toxicity, therefore
they play an important role in pharmaceutical research [14].
In cancer therapy, many plant-derived drugs such as vincris-
tine, paclitaxel and taxol have been identiﬁed and developed.
As reported, TAT2 isolated from A. tonkinensis showed
promising anticancer properties in vitro [5]. Therefore, we
assessed the antitumor activity of this compound in vivo.
Because of its high tumorigenic properties, the LLC cell line
was selected to create a tumor model for this study. TAT2
caused a signiﬁcant decrease in tumor growth at various
doses, being the most effective at a dose of 200 mg/kg body
weight.
Inﬂammatory responses play critical roles in the evolution of
cancer from initiation to metastasis. It has become evident that
the inﬂammatory microenvironment is an essential component
of all tumors [15]. Solid tumor growth induces a region of
hypoxia, stimulating necrosis in the tumor's core. In addition,
malignant cells also produce many cytokines and chemokines
that attract leukocytes [15,16]. Today, inﬂammation has become
a target for cancer prevention and therapy [17]. In this study,
the decreased WBC count including LYM indicated that
inﬂammation was reduced in mice administrated TAT2. This
result was in accordance with other reported effects that
A. tonkinensis exerted immunomodulatory activity against
disorders of chronic inﬂammation such as rheumatoid arthritis
[3,6]. Some compounds isolated from this plant, including
TAT2, were found to cause an anti-inﬂammatory effect due to
the inhibition of T-cell proliferation at high concentrations [3].
This explains why the number of LYM was reduced at the
highest dose of TAT2 but not at the lowest dose (50 mg/kg
body weight) compared to the negative control.
In addition to inﬂammation, anemia is a common phenom-
enon in patients with cancer and impacts survival and quality of
life [18]. Anemia causes multiple function disturbances of
various organs and tissues [19]. The management of anemia in
cancer patient has to improve treatment efﬁcacy and increase
survival [20]. In cancer, anemia occurs due to the reduction of
RBC count and Hb levels. Increasing the RBC count and Hb
content in TAT2-administrated mice indicated that this com-
pound may improve the hematopoietic system and survival rate.Further, TAT2 had low toxicity when studied in mice. Ac-
cording to these results, TAT2 has potential as an antitumor
agent.
In conclusion, the results of the present study indicate that
TAT2 can be isolated from A. tonkinensis leaves in large
quantities (0.2%). Furthermore, in vivo tests demonstrated a
signiﬁcant inhibition of tumor growth at 100 and 200 mg/kg
body weight. These results indicate that TAT2, a potential
antitumor agent from A. tonkinensis, may be valuable for pre-
paring functional foods and pharmaceutical medicines.
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